Treatment compliance of working persons to high-dose antimuscarinic therapies: a randomized trial

Kosilov, Kirill; Loparev, Sergey; Kuzina, Irina; Shakirova, Olga; Zhuravskaya, Natalya S.; Lobodenko, Alexandra

doi:10.1177/1756287216652030

Cited by 8 publications

(4 citation statements)

References 31 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…However, a decrease in the sexual life quality and libido (against the background of dutasteride administration), as well as the maintenance of hyperactivity symptoms can lead to psycho-emotional lability of patients, reactive depression, and refusal of further treatment. There are numerous studies, including our own, which indicated a significant decrease in medication adherence, and even a rejection of it in case of the absence of a relatively rapid positive effect [ [25] , [26] , [27] ]. Nevertheless, methods for rapid and safe correction symptoms of obstruction and hyperactivity and sexual dysfunction in the dutasteride treatment of BPH are not currently fully studied.…”

Section: Introductionmentioning

confidence: 99%

Efficacy of a combination of dutasteride, tadalafil, and solifenacin in the treatment of previously unsuccessful patients

Kosilov

Kuzina

Kuznetsov

et al. 2022

Asian Journal of Urology

Self Cite

View full text Add to dashboard Cite

Section: Introductionmentioning

confidence: 99%

Efficacy of a combination of dutasteride, tadalafil, and solifenacin in the treatment of previously unsuccessful patients

Kosilov

Kuzina

Kuznetsov

et al. 2022

Asian Journal of Urology

Self Cite

View full text Add to dashboard Cite

“…Higher education level is a well-known factor associated with adherence to MRA and other drugs. Previous studies have reported better compliance to antimuscarinic therapy among individuals with higher incomes [ 28 ], which is highly related to educational level. Better adherence among patients with a short duration of OAB symptoms may be explained by a shorter period of therapy duration.…”

Section: Discussionmentioning

confidence: 99%

Regular and Irregular Use and Reasons for Discontinuation of Solifenacin Therapy in Patients with Overactive Bladder Managed by Urologists

Małkowski,

Almgren-Rachtan,

Olszanecka-Glinianowicz

et al. 2024

Pharmaceuticals

View full text Add to dashboard Cite

Solifenacin, a selective muscarinic receptor antagonist, is one of the best-tolerated and most effective medicines that relieve storage symptoms in patients with an overactive bladder (OAB). However, the persistence of solifenacin in daily clinical practice remains far below that reported in clinical trials. This study aimed to analyze the adherence of patients to the therapy and the reasons for solifenacin discontinuation and non-regular use in OAB patients managed by urologists. Data concerning non-compliance and the discontinuation of solifenacin, along with the reasons, were collected during two consecutive visits for 64,049 OAB outpatients. Over the two visits, 81.6% of the patients continued therapy, and 88.6% were taking solifenacin regularly. An age ≥ 75 yrs., the male sex, a rural or small-city dwelling, and a prescription of ≥10 mg predicted therapy continuation. The female sex, a higher education, a short or long duration of an OAB, and a non-idiopathic OAB predicted regular use. The persistence of nycturia and urinary incontinence during therapy predicted both discontinuation and non-regular use. Dissatisfaction with therapy was the most frequent reason for discontinuation. In conclusion, an initial prescription of solifenacin at a low dose reduces the chance of OAB symptom improvement and results in more frequent discontinuation. A high rate of discontinuation related to dissatisfaction suggests unrealistic expectations for OAB patients and insufficient education by urologists.

show abstract

“…After consultation with an expert panel of urologists and observation of clinical practice in Iran, solifenacin 5 and/or 10 mg was selected as the comparison arm in the first-line of treatment and tolterodine 2 and/or 4 mg as the second-line. The data from randomized controlled trials (SYNERGY II) and meta-analysis of international studies were used to obtain efficacy and clinical safety parameters (16)(17)(18)(19).…”

Section: Model Overview and Outcomesmentioning

confidence: 99%

Cost-Utility Analysis of Mirabegron Compared to Solifenacin in the Treatment of Overactive Bladder (OAB) in Iran

Karimi Majd,

Mohammadnezhad,

Taheri

et al. 2023

Iran J Pharm Res

View full text Add to dashboard Cite

Background: Overactive bladder (OAB) is a symptomatic condition characterized by urinary urgency with or without incontinence, usually associated with frequent daytime urination, enuresis, and nocturia. Objectives: This economic evaluation was aimed at assessing the cost-effectiveness of mirabegron versus solifenacin in the treatment of OAB patients from a payer’s perspective in Iran. Methods: A Markov model with a 5-year time horizon was used. The model consisted of five health states, and OAB patients with an average age of 60 years entered the cycle from the persistent state. Transition probabilities were based on published trials, clinical judgments, and expert opinions. Resource use and costs, including those for medications and adverse events, were extracted from the literature and tariff book, and all costs are presented in 2019 US dollars with a 5% discount rate for the costs and utilities. The incremental cost-effectiveness ratio (ICER) and quality-adjusted life-years (QALYs) were computed for medications, and sensitivity analyses were used to test the robustness of the results. Results: Average per-patient treatment costs were $24,720.7 and $24,668.6 for mirabegron and solifenacin, respectively. Mirabegron was expected to produce higher QALYs than solifenacin (3.20 vs. 3.19). Mirabegron had an ICER of $531.3 over solifenacin, lower than the willingness-to-pay (WTP) threshold. The probabilistic analysis showed mirabegron cost-effectiveness in 80% of simulations at the WTP of $2709/QALY. Conclusions: Compared to solifenacin, mirabegron was more cost-effective in OAB patients in the Iranian healthcare system.

show abstract

Treatment compliance of working persons to high-dose antimuscarinic therapies: a randomized trial

Abstract: As a result of this study, under the control of the objective functional state of LUT, the influence of various factors on the patients' stability in the treatment with AM drugs was revealed.

Cited by 8 publications

References 31 publications

Efficacy of a combination of dutasteride, tadalafil, and solifenacin in the treatment of previously unsuccessful patients

Efficacy of a combination of dutasteride, tadalafil, and solifenacin in the treatment of previously unsuccessful patients

Regular and Irregular Use and Reasons for Discontinuation of Solifenacin Therapy in Patients with Overactive Bladder Managed by Urologists

Cost-Utility Analysis of Mirabegron Compared to Solifenacin in the Treatment of Overactive Bladder (OAB) in Iran

Contact Info

Product

Resources

About